Enterprise Europe Network

Stem cell extracellular vesicles therapy to turn off ischemic inflammation

Country of origin:
Country: 
ITALY
Opportunity:
External Id: 
TOIT20190717001
Published
23/07/2019
Last update
23/07/2019
Expiration date
23/07/2020

Keywords

Partner keyword: 
Gene - DNA Therapy
Stem cell Technologies
Cellular and Molecular Biology
Stem cells and biobanks
Cardiology
Circulatory diseases
Hospital activities
Other human health activities
EXPRESS YOUR INTEREST

Summary

Summary: 
A leading Italian public medical research centre committed to healthcare and translational medicine has developed an innovative therapeutic solution based on extracellular vesicles (EV) for treatment of secondary damage effects on ischemic tissues. The medical research centre is looking for industrial partners interested in a licensing agreement or a technical cooperation agreement.

Description

Description: 

Disorders characterized by ischemia/reperfusion, such as myocardial infarction, stroke, and peripheral vascular disease, continue to be among the most frequent causes of debilitating disease and death. Currently, no broad and effective therapeutic approaches are available most of all due to the very short timeframe (3-6 hours) from stroke symptom onset in which a patient is eligible to receive the tissue plasminogen activator, the only thrombolytic agent able to reduce the secondary effects of ischemia.
The Italian public medical research centre has selected and isolated human mesenchymal stem cells, renowned for their beneficial effects in pathological contexts of acute damage. After a reprogramming process (repCBMSC), the researchers identified a specific set of microRNA (miRNA) able to modulate inflammation in both parental Cord Blood Mesenchymal Stromal Cells - Extracellular vesicles (CBMSC-EV) and Reprogrammed Cord Blood Mesenchymal Stromal Cells - Extracellular vesicles (repCBMSC-EV). This set of miRNA was successfully challenged in a model of brain ischemia, where necrosis was significantly reduced.
The Italian medical research centre is looking for industrial partners interested in a licensing agreement of the technology or in technical agreement for co-development.

Advantages & innovations

Cooperation plus value: 
The most innovative aspects of this technology are: - Protective/reparative effect correlated with significant tissue level reduction of apoptotic/inflammatory Tumor necrosis factor (TNFα, 4-fold) and Interferon gamma (INFγ, 3-fold). - Significant necrosis damage reduction.

Stage of development

Cooperation stage dev stage: 
Under development/lab tested

Partner sought

Cooperation area: 
Type and tasks of partner sought: industrial partner in the healthcare sector willing to commercialize the technology by specific license agreements or to collaborate with the medical centre to further the development of the technology by a technical agreement.

Type and size

Cooperation task: 
>500 MNE,251-500,SME 51-250,>500